Business Description
Nautilus Biotechnology Inc
NAICS : 541714
SIC : 2834
ISIN : US63909J1088
Share Class Description:
NAUT: Ordinary SharesTotal Employee Number:
130Description
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.32 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.5 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.3 | |||||
3-Year EPS without NRI Growth Rate | -0.7 | |||||
3-Year FCF Growth Rate | -2.2 | |||||
3-Year Book Growth Rate | -21.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.13 | |||||
9-Day RSI | 49.56 | |||||
14-Day RSI | 45.97 | |||||
3-1 Month Momentum % | -35.7 | |||||
6-1 Month Momentum % | 27 | |||||
12-1 Month Momentum % | 253.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.85 | |||||
Quick Ratio | 11.85 | |||||
Cash Ratio | 11.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 0.83 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -33.74 | |||||
ROA % | -28.24 | |||||
ROIC % | -77.63 | |||||
3-Year ROIIC % | 4.28 | |||||
ROC (Joel Greenblatt) % | -213.18 | |||||
ROCE % | -33.08 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.07 | |||||
Price-to-Tangible-Book | 2.07 | |||||
EV-to-EBIT | -3.63 | |||||
EV-to-EBITDA | -4.03 | |||||
EV-to-Forward-Revenue | 39.93 | |||||
EV-to-FCF | -4.53 | |||||
| Price-to-Net-Current-Asset-Value | 4.54 | |||||
| Price-to-Net-Cash | 4.82 | |||||
Earnings Yield (Greenblatt) % | -27.55 | |||||
FCF Yield % | -17.15 |
GF Valueâ„¢
Nautilus Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nautilus Biotechnology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-28 08:30 | In 126 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:30 | In 37 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 36 days | ||
| General meeting for 2026 | 2026-06-17 10:00 | 2.17 (-3.56%) | ||
| Alliance Global Partners Annual Virtual Healthcare Conference | 2026-05-20 | 2.38 (+0.85%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 08:30 | 2.57 (-2.28%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 2.57 (-2.28%) | ||
| Investor Summit Group Virtual Conference` | 2026-03-25 13:00 | 3.95 (+6.47%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 10:30 | 2.42 (+0.00%) |
Show
Entries
Guru Commentaries on NAS:NAUT
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nautilus Biotechnology Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers